



BÖLÜM 1

Megakaryopoez ve Trombosit Formasyonu

Aslıhan SEZGİN¹

Giriş

Megakaryosit (MK) platelet oluşumundan sorumlu kök hücredir. Megakaryopoez ise kemik iliğinde hematopoietik kök hücreden (HKH) myeloid seri boyunca megakaryositlerin gelişimi ve olgunlaşmasını tanımlar. Olgunlaşan megakaryositler daha sonra bazı aşamalardan geçerek trombosit oluşumuna hazır hale gelecektir.

Megakaryositler ortalama 50-100 µm çapında ve 4700 fL hacminde olup çekirdekli kemik iliği hücrelerinin % 0,5-1'ini oluştururlar. Ortalama 1000-3000 trombosit üretirler (1,2).

Megakaryositler diferansiyasyon boyunca karmaşık bir olgunlaşma sürecinden geçer. Hücre siklusları geç anafazda sonlanır. Megakaryosit öncelikle normal 2N bölünme siklusundan geçer. Hücre siklusu daha sonra geç anafazda durarak (karyokinez ve sitokinezde) 4N, 8N, 16N ve 128N'e kadar DNA içeriğine sahip olabilen tek poliploid bir nukleusa sahip olur. Bu DNA içeriği çok loblu tek bir nukleusta bulunur ve her lob bir diploid DNA'yı (2N) temsil eder (Resim 1). Bu sürece endomitoz denir (3,4).

Endomitoz ve poliploidinin daha sonraki platelet sentezi için gerekli protein ve membran sentezine yönelik olduğu öne sürülmektedir (5).

Sitokinez sırasında aktive RhoA orta zonda miyozin aktivasyonu ve aktin polimerizasyonunda görev alarak kontraktil ring oluşumunda rol oynar. RhoA kinaz inhibisyonu ile sitokinezin sonlanması poliploid nukleus ile sonuçlanır (6). Siklin D3 artışı siklin B1 düzeyinde azalma, siklin bağımlı kinaz inhibitörleri de endomitozda rol oynar (7,8).

¹ Uzm. Dr., Altunizade Acıbadem Hastanesi, a5l1han@hotmail.com

Kaynaklar

1. Ebaugh FG Jr, Bird RM. The normal megakaryocyte concentration in aspirated human bone marrow. *Blood*. 1951;6:75–80
2. Harker LA, Finch CA. Thrombokinetik in man. *J Clin Invest* 1969; 48:963.
3. Bluteau D, Lordier L, Di Stefano A, et al. Regulation of megakaryocyte maturation and platelet formation. *J Thromb Haemost* 2009;7 1:227–234.
4. Vitrat N, Cohen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. *Blood* 1998;91:3711–3723.
5. Raslova H, Roy L, Vourc'h C, et al. Megakaryocyte polyploidization is associated with a functional gene amplification. *Blood* 2003;101:541–544.
6. Slayton WB, Wainman DA, Li XM, et al. Developmental differences in megakaryocyte maturation are determined by the microenvironment. *Stem Cells* 2005;23:1400-8.
7. Zimmet JM, Toselli P, Ravid K. Cyclin D3 and megakaryocyte development: exploration of a transgenic phenotype. *Stem Cells* 1998; 16 Suppl 2:97.
8. Zhang Y, Wang Z, Liu DX, et al. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. *J Biol Chem* 1998; 273:1387.
9. Palis J, Yoder M. C. Yolk-sac hematopoiesis: the first blood cells of mouse and man. *Exp. Hematol*. 2001; 29: 927-936
10. Galloway JL, Zon LI. Ontogeny of hematopoiesis: Examining the emergence of hematopoietic cells in the vertebrate embryo. *Curr Top Dev Biol*. 2003;53:139–158
11. Cumano A., Godin I. Ontogeny of the hematopoietic system. *Annu. Rev. Immunol*. 2007;25: 745-785
12. Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. *Br J Haematol* 2013;161:778-93
13. Cabezas-Wallscheid N, Klimmeck D, Hansson J, et al. Identification of regulatory networks in hscs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. *Cell Stem Cell*. 2014;15:507–522
14. Berridge MV, Ralph SJ, Tan AS. Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb-IIIa glycoprotein complex. *Blood* 1985; 66:76.
15. Schulze H, Korpall M, Hurov J, et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. *Blood* 2006;107:3868–3875.
16. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. *Science* 2007;317:1767–1770.
17. Greenberg SM, Kuter DJ, Rosenberg RD. In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. *J Biol Chem* 1987; 262:3269.
18. Meng R, Wang Y, Yao Y, et al. SLC35D3 delivery from megakaryocyte early endosomes is required for platelet dense granule biogenesis and is differentially defective in Hermansky-Pudlak syndrome models. *Blood* 2012;120:404-14.
19. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. *J Clin Invest* 1989; 84:1320.
20. Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. *J Clin Invest* 1989; 84:73.
21. White JG. Serotonin storage organelles in human megakaryocytes. *Am J Pathol* 1971; 63:403.
22. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. *Blood* 2000; 96:4142.
23. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic

- growth factor receptor superfamily. *Proc Natl Acad Sci U S A* 1992;89:5640–5644.
24. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. *Science* 1994;265:1445–1447.
 25. Huang H, Cantor AB. Common features of megakaryocytes and hematopoietic stem cells: What's the connection? *J Cell Biochem*. 2009;107:857–864
 26. van den Oudenrijn S, Bruin M, Folman CC, Peters M, et al. Mutations in the thrombopoietin receptor, mpl, in children with congenital amegakaryocytic thrombocytopenia. *Br J Haematol*. 2000;110:441–448
 27. Miyakawa Y, Drachman JG, Gallis B, et al. A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-mpl. *J Biol Chem*. 2000;275:32214–32219
 28. Schulze H, Ballmaier M, Welte K, Germeshausen M. Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets. *Exp Hematol* 2000;28:294–304.
 29. Matsumura I, Ishikawa J, Nakajima K, et al. Thrombopoietin induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. *Mol Cell Biol* 1997;17:2933–2943.
 30. Kirito K, Watanabe T, Sawada K, et al. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. *J Biol Chem* 2002;277:8329–8337.
 31. Najfeld V, Cozza A, Berkofsky-Fessler W, et al. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2V617F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. *Exp Hematol* 2007;35:1668–1676.
 32. Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. *Br J Haematol* 1996; 95:227.
 33. Yang YC, Ciarletta AB, Temple PA, et al. Human il-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine il-3. *Cell*. 1986;47:3–10.
 34. Nishimura S, Nagasaki M, Kunishima S, et al. IL-1 α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. *J Cell Biol*. 2015;209:453–466.
 35. Chen S, Hu M, Shen M, et al. Igf-1 facilitates thrombopoiesis primarily through akt activation. *Blood*. 2018;132:210–222.
 36. Machlus KR, Johnson KE, Kulenthirarajan R, et al. Ccl5 derived from platelets increases megakaryocyte proplatelet formation. *Blood*. 2016;127:921–926.
 37. Nagai R, Matsuura E, Hoshika Y, et al. RUNX1 suppression induces megakaryocytic differentiation of UT-7/GM cells. *Biochem Biophys Res Commun* 2006;345:78–84.
 38. Berger R, Busson M, Dastugue N, et al. Acute megakaryoblastic leukemia and loss of the RUNX1 gene. *Cancer Genet Cytogenet* 2006;164:71–3.
 39. Takahashi S, Komeno T, Suwabe N, et al. Role of GATA1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. *Blood* 1998;92:434–42.
 40. Wang X, Crispino JD, Letting DL, et al. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. *Embo Journal* 2002;21:5225–34.
 41. Eisbacher M, Holmes ML, Newton A, et al. Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. *Mol Cell Biol* 2003;23:3427–3441.
 42. Starck J, Cohet N, Gonnet C, et al. Functional crossantagonism between transcription factors FLI-1 and EKLF. *Mol Cell Biol* 2003;23:1390–1402.
 43. Metcalf D, Carpinelli MR, Hyland C, et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. *Blood* 2005;105:3480–3487.

44. Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. *Dev Cell* 2008;14:843–853.
45. Chou ST, Khandros E, Bailey LC, et al. Graded repression of PU.1/ Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. *Blood* 2009;114:983–994.
46. Fock EL, Yan F, Pan S, et al. NF-E2-mediated enhancement of megakaryocytic differentiation and platelet production in vitro and in vivo. *Exp Hematol* 2008;36:78–92.
47. Patel SR, Hartwig JH, Italiano JE, Jr. The biogenesis of platelets from megakaryocyte proplatelets. *J Clin Invest* 2005;115:3348–54.
48. Patel-Hett S, Wang H, Begonja AJ, et al. The spectrinbased membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. *Blood* 2011;118:1641–52.
49. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. *Blood* 2002; 100:1310.
50. Lane WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. *Blood* 2000; 96:4152.
51. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor cxcr4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. *Blood*. 1998;92:756–764.
52. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by cxcl12-cxcr4 chemokine signaling in bone marrow stromal cell niches. *Immunity*. 2006;25:977–988
53. Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through cxcl4 secretion. *Nat Med*. 2014;20:1315–1320.
54. Jiang J, Kao CY, Papoutsakis ET. How do megakaryocytic microparticles target and deliver cargo to alter the fate of hematopoietic stem cells? *J Control Release*. 2017;247:1–18.
55. Abbonante V, Di Buduo CA, Gruppi C, et al. Thrombopoietin /tgfbeta1 loop regulates megakaryocyte extracellular matrix component synthesis. *Stem Cells*. 2016;34:1123–1133.
56. Eliades A, Papadantonakis N, Bhupatiraju A, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. *J Biol Chem*. 2011;286:27630–27638.
57. Abbonante V, Di Buduo CA, Gruppi C, et al. A new path to platelet production through matrix sensing. *Haematologica*. 2017;102:1150–1160.
58. Crist SA, Elzey BD, Ahmann MT, Ratliff TL. Early growth response-1 (egr-1) and nuclear factor of activated t cells (nfat) cooperate to mediate cd40l expression in megakaryocytes and platelets. *J Biol Chem*. 2013;288:33985–33996.
59. Zufferey A, Speck ER, Machlus KR, et al. Mature murine megakaryocytes present antigen-mhc class i molecules to t cells and transfer them to platelets. *Blood Adv*. 2017;1:1773–1785.
60. Markovic B, Wu Z, Chesterman CN, Chong BH. Quantitation of soluble and membrane-bound fc gamma riiia (cd32a) mrna in platelets and megakaryoblastic cell line (meg-01). *Br J Haematol*. 1995;91:37–42.
61. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science*. 2010;327:580–583.